Using advanced MRI to tell apart tumor recurrence from false alarms in brain cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study explores the effectiveness of advanced diffusion-weighted MRI (ADW-MRI) in distinguishing between true tumor progression and pseudoprogression in patients diagnosed with glioblastoma or brain metastases. The study will utilize conventional MRI alongside ADW-MRI when there is suspicion of tumor recurrence, particularly in cases where surgical resection may be necessary. Histopathological findings from resected tissue will be correlated with ADW-MRI results to assess the accuracy of this imaging technique. The primary goal is to evaluate the feasibility of this approach and analyze the relationship between imaging features and tissue characteristics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection.
* Able to give informed consent

Exclusion Criteria:

* Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy)
* Patients in a life-threatening condition
* Patients in need of emergent surgery
* Histopathological analyses of insufficient quality
* Unable to give informed consent
* Age \<18 Years

Where it's running

• University Hospital Basel
  Basel, Switzerland Recruiting

Study contacts

• Principal investigator: Dominik Cordier, PD Dr. med. — University Hospital, Basel, Switzerland
• Study coordinator: Dominik Cordier, PD Dr. med.
• Email: dominik.cordier@usb.ch
• Phone: +41 61 26 56 42

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771

  This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07648823

• Personalized Targeted Glioblastoma Therapies Guided by Ex Vivo Drug Screening

  This trial tests whether using a patient’s own tumor cells to screen drugs can guide a personalized treatment plan for people with newly diagnosed glioblastoma undergoing short-course radiotherapy.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT07627334

• LITT for ultra-early GBM recurrence within 1 week of pre-radiation planning

  This study tests whether a minimally invasive laser treatment can destroy an early GBM recurrence without delaying planned radiotherapy and chemotherapy.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT07616986

• Combined intracranial and intravenous NK cell therapy for malignant brain tumors

  This trial will test whether giving adults with recurrent malignant brain tumors their own expanded and activated natural killer (NK) cells into the tumor site and into the bloodstream is safe and feasible.

  Recruiting at 3 sites Peking University Third Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07552233

• Preventive intrathecal thiotepa with standard chemoradiation for high‑risk glioblastoma

  This trial tests whether adding six weekly intrathecal injections of thiotepa to standard chemoradiation can lower leptomeningeal spread and improve outcomes for adults with newly diagnosed GBM that contacts the subventricular zone or had ventricular entry during surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07511725

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.